Rimactan 300 mg Norge - norsk - Statens legemiddelverk

rimactan 300 mg

sandoz gmbh - rifampicin - kapsel, hard - 300 mg

Rimactan 300 mg Norge - norsk - Statens legemiddelverk

rimactan 300 mg

2care4 aps - rifampicin - kapsel, hard - 300 mg

Rimcure Norge - norsk - Statens legemiddelverk

rimcure

sandoz - københavn - rifampicin / isoniazid / pyrazinamid - tablett, filmdrasjert - 150 mg / 75 mg / 400 mg

Trimonil Retard 300 mg Norge - norsk - Statens legemiddelverk

trimonil retard 300 mg

orifarm as - karbamazepin - depottablett - 300 mg

Trimonil Retard 300 mg Norge - norsk - Statens legemiddelverk

trimonil retard 300 mg

orifarm as - karbamazepin - depottablett - 300 mg

Rimstar Norge - norsk - Statens legemiddelverk

rimstar

2care4 aps - rifampicin / isoniazid / pyrazinamid / etambutolhydroklorid - tablett, filmdrasjert - 150 mg / 75 mg / 400 mg / 275 mg

Rimactan 300 mg Norge - norsk - Statens legemiddelverk

rimactan 300 mg

orifarm as - rifampicin - kapsel, hard - 300 mg

Qinlock Den europeiske union - norsk - EMA (European Medicines Agency)

qinlock

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinal stromal tumors - antineoplastiske midler - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Gavreto Den europeiske union - norsk - EMA (European Medicines Agency)

gavreto

roche registration gmbh  - pralsetinib - karsinom, ikke-småcellet lunge - antineoplastiske midler - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Tivicay Den europeiske union - norsk - EMA (European Medicines Agency)

tivicay

viiv healthcare bv - dolutegravir - hiv-infeksjoner - antivirale midler til systemisk bruk - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg. tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.